icon3

Next-Generation Sequencing (NGS) Market By Application (Diagnostics, Biomarkers and Cancer, Reproductive Health), By Technology (Ion, SMRT) By Product Type (Instruments, Reagents & Consumables) Regional Analysis & Forecast - 2026

  • OI-120
  • |
  • Published date: May, 2019
  • |
  • In Vitro Diagnostics
  • |
  • 0 Pages

Next-generation sequencing (NGS), also known as high-throughput sequencing, it is a powerful platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously. This powerful tool is revolutionizing fields such as personalized medicine, genetic diseases, and clinical diagnostics by offering a high throughput option with the capability to sequence multiple individuals at the same time. Using NGS an entire human genome can be sequenced within a single day

Market Overview


The overall global Next-Generation Sequencing market is expected to grow at a significant CAGR rate of xx% from USD xx billion in 2018 to USD xx billion in 2026. The major factors such as rapid adoption of this technology by researchers and its usability as a substitute of microarray technology in addition to its higher throughput, increased accuracy, and affordable costs are driving the next generation sequencing market growth. However, factors such as reducing capital expenditure from academic institutions and huge dependability on grants funding from the government are hampering the next generation sequencing market growth. In addition, the analysis of a large amount of data generated by sequencers, and data storage and management are posing a major challenge. The growth opportunities of this market include cloud computing, rising demand for pre-sequencing, developments in NGS fully integrated instruments and rising nanopore sequencing technology. There is a huge opportunity for this technology in the field of drug discovery, personalized medicine, agricultural and animal research.


Moreover, due to the rapid development of companion diagnostics in bringing advanced genomic and personalized medicine, is poised to increase the market growth in the near future. The advent of targeted therapies in oncology and other fields has significantly transformed the companion diagnostics. The NGS techniques are likely to help expand the companion diagnostics vertical, as NGS panels are capable of measuring several biomarkers in one test. Consequently, this makes the NGS method as ideal targeted therapies in delivering precision medicine. NGS services segment is anticipated to be a promising segment during the estimated period.


Key Developments



  • May 06, 2019 – FBI approves Verogen's Next-Gen Forensic DNA technology for National DNA Index System

  • March 12, 2018: QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN’s GeneReader NGS System.


Segmentation


The next generation sequencing market is segmented based on product, application, technology, end user, and geography.


By Application: Diagnostics, Biomarkers and Cancer, Reproductive Health


By Technology: Ion, SMRT, Illumina


By End-users: Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other End Users


By Product Type: Instruments, Reagents & Consumables


By Geography: America, Europe, Asia Pacific, and the Middle East and Africa.


The North American region accounts for the largest share of the next generation sequencing market. The European and Asian markets are also expected to grow due to the favorable funding from the government to adopt this technology. The major factors contributing to this market growth include rising adoption by new customers, rising adoption of high-throughput sequencing platforms by government organizations such as Biotechnology and Biological


Some of the key players operating in the global NGS market include Thermo Fisher Scientific, Inc., Illumina, Inc. Pacific Biosciences of California, Inc., Qiagen N.V., Roche, Agilent Technologies, Inc., Perkinelmer, Inc.

The report covers in-depth analysis of the Global Next-Generation Sequencing (NGS) Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), By Application (Diagnostics, Biomarkers and Cancer, Reproductive Health), By Technology (Ion, SMRT). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.


The report includes in-depth company profiles of key players in the Global Next-Generation Sequencing (NGS) Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


Scope:



  • Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Next-Generation Sequencing (NGS)

  • Provides a comparative analysis of key marketed products and pipeline market products.

  • Provides key information on players involved in the Global Next-Generation Sequencing (NGS) Market

  • Provides a complete overview of market segments and the regional outlook of Global Next-Generation Sequencing (NGS) Market

  • Provides in-depth coverage of key news related to global Next-Generation Sequencing (NGS) Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 








  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 








  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 








  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.





REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Coporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)